Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion03:48

Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion

31.4K
Although gaseous molecules travel at tremendous speeds (hundreds of meters per second), they collide with other gaseous molecules and travel in many different directions before reaching the desired target. At room temperature, a gaseous molecule will experience billions of collisions per second. The mean free path is the average distance a molecule travels between collisions. The mean free path increases with decreasing pressure; in general, the mean free path for a gaseous molecule will be...
31.4K
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

4.4K
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
4.4K
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

797
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
797
Psychodynamic Perspectives on Personality01:27

Psychodynamic Perspectives on Personality

1.6K
The psychodynamic perspective in psychology asserts that most personality functions operate unconsciously, outside of awareness. This means that the motives and emotions driving behavior often remain hidden, automatically buried in the unconscious mind as a defense mechanism to shield us from psychological distress. According to this theory, the unconscious mind contains thoughts, memories, and emotions that are too disturbing to face directly.
Psychodynamic theorists argue that unconscious...
1.6K
Criticisms of the Evolutionary Perspective01:23

Criticisms of the Evolutionary Perspective

376
In a study where individuals posing as strangers offered compliments and proposed casual sex to students, the responses differed significantly based on gender. Not a single woman accepted the proposal, while 70% of the men agreed. This outcome provides a useful scenario to explore through the lens of evolutionary psychology and social learning theory, highlighting the diverse perspectives on human sexual behaviors.
Evolutionary psychology provides one explanation for these findings, suggesting...
376
The Behavioral Perspective on Personality01:19

The Behavioral Perspective on Personality

838
Behaviorists view personality as primarily shaped by environmental reinforcements and consequences. According to this perspective, behavior is influenced by external stimuli, and individuals adjust their actions based on rewards and punishments. Over time, learning histories — accumulated patterns of reinforcement — play a significant role in shaping personality. Behaviors that lead to positive outcomes are reinforced, while those resulting in negative outcomes are diminished.
838

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal of medical economics·2025
Same author

How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?

Immunotherapy·2025
Same author

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Blood·2025
Same author

Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review.

Expert opinion on investigational drugs·2025
Same journal

ELOVL6 Promotes the Proliferation and Migration of Oral Squamous Cell Carcinoma Cells Through Fatty Acid Remodelling and ROS Modulation in vitro.

OncoTargets and therapy·2026
Same journal

<i>NR5A2</i> Promotes Cell Growth and Resistance to Temozolomide Through Regulating Notch Signal Pathway in Glioma [Retraction].

OncoTargets and therapy·2026
Same journal

Primary Hepatic Epithelioid Gastrointestinal Stromal Tumor: A Rare Case.

OncoTargets and therapy·2026
Same journal

MiR-153-3p Suppresses Cell Proliferation, Invasion and Glycolysis of Thyroid Cancer Through Inhibiting E3F3 Expression [Retraction].

OncoTargets and therapy·2026
Same journal

lncRNA CASC9 Regulates Cell Migration and Invasion in Hemangioma Endothelial Cells by Targeting miR-125a-3p/Nrg1 [Retraction].

OncoTargets and therapy·2026
Same journal

MFAP2 Promotes Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Activating TGF-β/SMAD2/3 Signaling Pathway [Retraction].

OncoTargets and therapy·2026
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

Perspectives on Neuroscience
26:41

Perspectives on Neuroscience

Published on: July 31, 2007

5.3K

Primary effusion lymphoma: current perspectives.

Mayur Narkhede1, Shagun Arora2, Chaitra Ujjani1

  • 1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA, csu@georgetown.edu.

Oncotargets and Therapy
|July 11, 2018
PubMed
Summary
This summary is machine-generated.

Primary effusion lymphoma (PEL), a rare cancer linked to human herpesvirus type-8, affects immunocompromised individuals. This review covers PEL pathogenesis, current treatments, and promising targeted therapies for frontline and relapsed disease.

Keywords:
HHV8-associated lymphomasHIV-associated lymphomasprimary effusion lymphoma

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.5K

Related Experiment Videos

Last Updated: Feb 8, 2026

Perspectives on Neuroscience
26:41

Perspectives on Neuroscience

Published on: July 31, 2007

5.3K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.5K

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Primary effusion lymphoma (PEL) is an aggressive malignancy associated with human herpesvirus type-8 (HHV-8).
  • PEL predominantly affects elderly or immunocompromised patients, frequently presenting as body cavity effusions.
  • Patients often have underlying conditions like HIV, complicating treatment decisions.

Purpose of the Study:

  • To review the pathogenesis of primary effusion lymphoma.
  • To discuss current and emerging management strategies for PEL in both frontline and relapsed settings.
  • To highlight targeted agents showing therapeutic promise for PEL.

Main Methods:

  • Literature review of pathogenesis and treatment of primary effusion lymphoma.
  • Analysis of current clinical practices and investigational therapies.
  • Synthesis of data on molecular drivers and environmental factors in PEL.

Main Results:

  • Chemotherapy is standard for fit patients, but no optimal regimen exists.
  • High relapse rates (6-8 months) necessitate further treatment options.
  • Expanding knowledge of PEL's molecular landscape is guiding new therapeutic approaches.

Conclusions:

  • Understanding PEL pathogenesis is crucial for developing effective treatments.
  • A multi-faceted approach combining chemotherapy and targeted agents may improve outcomes.
  • Further research into targeted therapies is essential for managing this aggressive lymphoma.